TY - JOUR
T1 - Pancreatic Cancer
T2 - Nucleic Acid Drug Discovery and Targeted Therapy
AU - Dai, Hong
AU - Abdullah, Razack
AU - Wu, Xiaoqiu
AU - Li, Fangfei
AU - Ma, Yuan
AU - Lu, Aiping
AU - Zhang, Ge
N1 - Funding Information:
This study was supported by the Guangdong Basic and Applied Basic Research Foundation (2020A1515110630), the Hong Kong General Research Fund (HKBU 12114416, HKBU 12101117, HKBU 12100918, HKBU 12101018, HKBU 12103519, and HKBU 14100218), the National Key R&D Program of China (2018YFA0800804).
Publisher Copyright:
© 2022 Dai, Abdullah, Wu, Li, Ma, Lu and Zhang.
PY - 2022/5/16
Y1 - 2022/5/16
N2 - Pancreatic cancer (PC) is one of the most lethal cancers with an almost 10% 5-year survival rate. Because PC is implicated in high heterogeneity, desmoplastic tumor-microenvironment, and inefficient drug-penetration, the chemotherapeutic strategy currently recommended for the treatment of PC has limited clinical benefit. Nucleic acid-based targeting therapies have become strong competitors in the realm of drug discovery and targeted therapy. A vast evidence has demonstrated that antibody-based or alternatively aptamer-based strategy largely contributed to the elevated drug accumulation in tumors with reduced systematic cytotoxicity. This review describes the advanced progress of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), messenger RNA (mRNAs), and aptamer-drug conjugates (ApDCs) in the treatment of PC, revealing the bright application and development direction in PC therapy.
AB - Pancreatic cancer (PC) is one of the most lethal cancers with an almost 10% 5-year survival rate. Because PC is implicated in high heterogeneity, desmoplastic tumor-microenvironment, and inefficient drug-penetration, the chemotherapeutic strategy currently recommended for the treatment of PC has limited clinical benefit. Nucleic acid-based targeting therapies have become strong competitors in the realm of drug discovery and targeted therapy. A vast evidence has demonstrated that antibody-based or alternatively aptamer-based strategy largely contributed to the elevated drug accumulation in tumors with reduced systematic cytotoxicity. This review describes the advanced progress of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), messenger RNA (mRNAs), and aptamer-drug conjugates (ApDCs) in the treatment of PC, revealing the bright application and development direction in PC therapy.
KW - antisense oligonucleotides
KW - aptamer-drug conjugates
KW - nucleic acid drugs
KW - pancreatic cancer
KW - small interfering RNAs
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85131450894&partnerID=8YFLogxK
U2 - 10.3389/fcell.2022.855474
DO - 10.3389/fcell.2022.855474
M3 - Journal article
AN - SCOPUS:85131450894
SN - 2296-634X
VL - 10
JO - Frontiers in Cell and Developmental Biology
JF - Frontiers in Cell and Developmental Biology
M1 - 855474
ER -
